Azoospermia is defined as the absence of sperm in at least two different ejaculates (1) . Contrary to most other sperm defects which can be treated by assisted reproductive technologies (ART) using in vitro fertilization, often in combination with intracytoplasmic sperm injection (ICSI), azoospermia is often untreatable, highlighting the importance of focusing on this condition. When spermatogenesis is not completely abolished, ICSI can, however, be envisaged following testicular or epididymal biopsy. As a whole, azoospermia can nevertheless be placed among the most severe causes of male infertility and we believe that the study and elucidation of its molecular pathophysiologies are paramount to improving patient care and treatment.
The etiology of azoospermia can be broadly divided into three main categories: pre-testicular, testicular, and post-testicular. (i) Pre-testicular azoospermia can be caused by endocrine abnormalities mainly characterized by low levels of sex steroids and abnormal gonadotropin levels. These abnormalities can be congenital (e.g. Kallmann syndrome), acquired (e.g. hypothalamic or pituitary disorders) or secondary (mostly due to environmental factors such as endocrine disruptors or iatrogenic actions). (ii) Post-testicular causes include ejaculatory disorders or obstructions, which impair the transport of spermatozoa from the testis. These obstructions can be caused by a congenital bilateral absence of the vas deferens (CBAVD), or acquired following surgery (vasectomy), cancer, injury or infections. (iii) Testicular causes of azoospermia, which are discussed in most detail here, can also be congenital, acquired or idiopathic. Similar to obstructive causes of azoospermia, testicular causes include trauma, torsion, infections (e.g. mumps and orchitis), testicular tumors, iatrogenic effects, irradiation, surgery (compromising vascularization of testis), systemic diseases (cirrhosis and renal failure) or varicocele (2) . Testicular causes include genetic abnormalities (Y-chromosome deletions), germ cell aplasia (Sertoli cell-only syndrome, SCOS) or spermatogenesis arrest. The typical phenotype of testicular failure results in azoospermia or severe oligozoospermia (SO) (sperm density ≤5 × 10 6 /ml). Surprisingly, despite the abundance of genes known to be necessary for spermatogenesis [but identified only in animal models (3) ], Y-microdeletions and chromosomal abnormalities such as Kinefelter (47,XXY) have long remained the only known recurrent genetic cause of non-obstructive azoospermia (NOA) and SO. Nevertheless, most testicular defects are believed to have a genetic basis. At the present time, however, even after a complete diagnostic work-up, the etiology of primary testicular failure remains unknown in more than half of the cases (4, 5) .
NOA and SO resulting from defects in spermatogenesis, can be estimated to occur in 20-30% of infertile couples, azoospermia in 10% (6, 7) . It is estimated that 1% of all men are azoospermic. Because of this high incidence and the frequent use of gametes produced by inefficient spermatogenesis to conceive children through ART, it is critical to better understand the pathophysiology of infertility. Identifying the genetic causes of NOA and SO will not only permit improvement of current treatments but also the characterization of the primary and secondary defects affecting the gametes produced by NOA or SO men, and thus provide valuable insights into the consequences these defects might have on the health and development of future generations born by ART with gametes produced by a severely impaired spermatogenesis.
Our objective here is to provide a critical assessment of genetic variants that have been proposed as causes of a severe reduction in spermatozoa count. We focus on the monogenic defects directly affecting spermatogenesis or sperm function and we will not review the cases of secondary infertility due for instance to hormonal dysregulations or disorders of sexual development nor ejaculatory problems whether mechanical or psychological. Genetic defects having a direct qualitative effect on sperm morphology or function are also not described here but are detailed in our companion review. Finally, while a few animal models are introduced to provide information regarding gene function during spermatogenesis, the review focuses on gene defects that have been identified and causally linked to infertility in men with an unexplained reduction in spermatozoa count.
Genetic causes of severe quantitative reduction in sperm production
Frequent known genetic causes of non-obstructive male infertility
At the present time, only mutations on the Y-chromosome and chromosomal anomalies [mainly 47, XXY (Klinefelters syndrome)] have been unambiguously showed to be frequent genetic causes of non-obstructive male infertility (2) . Large recurrent multigene deletions of three azoospermia factor intervals (AZFa, AZFb or AZFc) on the Y-chromosome are found in approximately 3% of infertile men with a severely reduced sperm count (<1 × 10 6 /ml), and 10% of azoospermic men (8, 9) . The recurrent AZFc deletion is one of the most frequent known genetic causes of male infertility, and in a large study of 20,000 Y-chromosomes, it has been shown to be present in 1 in 2320 men and to be responsible for 6% of severe spermatogenic failure (10) .
Despite the fact that the first molecular description of AZF deletions was made almost 25 years ago (11), the gene or genes required for full male fertility in each AZF interval have not yet been identified. This is because most deletions are large and include multiple genes, and the rapid evolution of the Y-chromosome makes it difficult to model the function of AZF genes in the mouse. Large partial deletions of the AZFc interval have been described, but these do not remove all copies of the multicopy AZFc coding genes, DAZ, CDY1 and BPY2, and only have a modest negative effect on male fertility (10) . Smaller deletions or loss-of-function (LOF) mutations that affect a single coding gene in infertile men have only been convincingly reported for two genes, USP9Y (12) (13) (14) (15) in the AZFa interval, and HSFY (16) in the AZFb interval. Full AZFa deletions remove two genes, USP9Y and DDX3Y, and are associated with azoospermia due to SCOS, the most severe testis phenotype characterized by the complete absence of all germ cells in the testicular tubule. Full AZFb deletions remove all copies of HSFY, EIF1AY, KDM5D, RPS4Y2, PRY and RBMY1, and are associated with azoospermia consequent to a meiotic maturation arrest of germ cells (17) . Men lacking only either USP9Y or HSFY produce spermatozoa and can be naturally fertile, thus excluding USP9Y as necessary for germ cell survival and HSFY as necessary for meiotic progression in human.
Interestingly, it has recently been shown in the mouse that Eif2s3y, the Y gene required for spermatogonial proliferation (17) , is also essential for progression through meiosis (18) . Eif2s3y encodes a translation initiation factor, EIF2S3Y. The human Y-chromosome has no orthologue of Eif2s3y, but carries the EIF1AY gene, encoding a distinct translation initiation factor, EIF1AY.
Remarkably, the initiation factors encoded by Eif2s3y and EIF1AY are both directly involved in initiation codon recognition by the Met-tRNA (19) . This indicates that the efficiency of this step could be critical for male meiosis in mammals, and reveals EIF1AY as a strong candidate for the human meiotic factor in the AZFb interval.
A karyotype is the first genetic test that should be carried out for NOA. It permits detection of Klinefelter syndrome, which accounting for 14% of all azoospermia cases, is by far the most frequent genetic cause of infertility (7) . Karyotype analysis also allows detection of balanced translocations, which are found approximately 10 times more frequently in infertile men than in the general population and are found in more than 1% of azoospermia patients (7, 20) . The use of translocation cases to map infertility genes is complicated by the fact that they are often associated with chromosome pairing defects leading to meiotic arrest. Furthermore, the genes potentially participating in the testicular dysfunction associated with these chromosomal defects are multiple and individual genes cannot be singled out. Accumulating evidence suggests that for Klinefelter as well as for most translocation cases, gene dysregulation during meiosis in unsynapsed chromosome segments is responsible for the associated infertility phenotype. During male meiotic prophase I, the X and the Y-chromosomes are transcriptionally inactivated in a structure called the X-Y body, a structure comparable with the compacted inactive X-chromosome (Barr body), observed in all female cells (21, 22) . This mechanism has been described as meiotic silencing of unsynapsed chromatin, which silences chromosomes that fail to pair with their homologous partners and, in doing so, may protect against aneuploidy in subsequent generations (23) . In addition, this mechanism could inhibit the meiotic expression of X-and Y-linked genes that could have a toxic effect during meiosis and need to be repressed for adequate meiotic progression, such as has been showed for the Zfy1 and Zfy2 genes on the mouse Y-chromosome (24) . In Klinefelter, both X-chromosomes pair, they are not included in the X-Y body and are therefore not repressed and thus may produce potentially deleterious gene products. The opposite might occur in balanced translocation carriers. Pairing is impaired at translocation breakpoints leading to the inclusion of autosomal sequences in the X-Y body and their inappropriate inactivation, potentially resulting in the inactivation of genes necessary for basic cell functions or meiotic progression (25, 26) .
At the present time, karyotype analysis and screening for Y-microdeletion remain the most pertinent genetic tests in cases of NOA and SO. In the next chapters, we will review the genes that have been reliably showed to be involved in spermatogenic failure in human. We provide in Table 1 a detailed list of genes involved in spermatogenesis defects and provide their chromosomal localization (Chr.) and the frequency of the different variants indicated in the Exome Aggregation Consortium (ExAC).
Dominant causes of NOA and SO -candidate gene approach
Multiple sequencing efforts to identify mutations in individual candidate autosomal and X-linked genes in men with isolated infertility have not convincingly identified any major genetic causes of human male fertility. In 2014, it was estimated that 139 genes had been resequenced, finding mainly heterozygous mutations at a low frequency in the infertile cohorts and absent from controls (40) . An important consideration when interpreting results from this type of approach is that, because data are generated from one or a few genes only, it is rarely possible to know whether a variant is the primary cause of the infertility or one of several contributing factors. Two of the earliest studies of this type identified a rare LOF variant in the meiotic gene SYCP3 (synaptonemal complex protein 3) in men with a meiotic block (41), and three rare variants in KLHL10 (kelch like family member 10) in oligozoospermic men (42) . These are often cited as examples of primary genetic causes of male infertility. Recently, however, the Exome Aggregation Consortium (ExAC), (URL: http://exac.broadinstitute.org) has provided an exponential increase in our knowledge of human genetic variation and it is now indispensible to confront these earlier studies with this rich resource to reevaluate the strength of the link between a genetic variant and spermatogenic failure.
For SYCP3, 2 of 19 men with a meiotic block were found to be heterozygous for a rare frameshift mutation, p.Ile215LeufsTer2, predicted to result in the production of a truncated SYCP3 isoform lacking 19 C-terminal amino acids, and concluded to be a dominant cause of meiotic maturation arrest and azoospermia (41) . In ExAC, 1 in 166 individuals are heterozygotes for p.Ile215LeufsTer2. As it is estimated that 1 in 100 of all men are azoospermic, more than half the azoospermic men presenting at infertility clinics would be carriers of p.Ile215LeufsTer2, if it were causal of azoospermia. This was not the case in the original study or in a follow-up study of 53 men with meiotic maturation arrest (43) . It can therefore be formally excluded that p.Ile215LeufsTer2 is a dominant monogenic cause of male infertility.
For KLHL10, there is a good reason to believe that LOF variants could negatively affect fertility in the heterozygous state because, in the mouse, Klhl10 haploinsufficiency causes reduced production of functional spermatozoa (44) . Consistent with this also being the case in human, KLHL10 is flagged as intolerant to heterozygous LOF mutations in ExAC (2 LOF out of 60,706 individuals). Yatsenko et al. (42) found three alleles that were heterozygous in oligozoospermic men (n = 270) and absent from controls (n = 394): the pGln216Pro allele in four oligozoospermic men, the p.Ala313Thr allele in two unrelated SO men (∼5 × 10 6 sperm/ml) and a partial splicing anomaly observed at the RNA level, in a third SO men (1.7 × 10 6 sperm/ml). With the advantage of hindsight afforded by ExAC we can see that p.Gln216Pro is present in 1 in 35 African-Americans, and p.Ala313Thr in 1:850 Europeans, showing that both 
Chr., chromosome; ExAC, Exome Aggregation Consortium. TEX11 variants are designated on the basis of the transcript ENST00000395889.
alleles are transmitted by heterozygotes and are unlikely in isolation to be dominant causes of reduced sperm production and male infertility. The splicing anomaly could be causal of infertility, but requires further validation. In a single follow-up study, no pathogenic KLHL10 variants were found in a cohort of 196 SO men (45) . Similarly, two variants on the X-linked USP26 gene were described to be associated with SCOS and an absence of sperm in the ejaculate (46, 47) . It was then quickly showed that two of these variants actually corresponded to the ancestral sequence of the gene and were present in significant frequencies in sub-Saharan African and South and East Asian populations thus ruling out the link between these USP26 variants and SCOS (48) .
More recently, a large study used high-throughput sequencing to sequence 600 'infertility' genes in 766 NOA men and 521 fertile controls from China (49) . Results were published only for the HSF2 (heat shock transcription factor 2) gene. They found five patient-specific heterozygous missense mutations and functional tests indicated that one, p.R502H, had a dominant negative effect on the function of HSF2. This result cannot be confirmed in the mouse model because it has been shown that the loss of HSF2 function in the mouse affects somatic development, but does not greatly affect fertility because of functional redundancy with HSF1 (50), making this isolated case difficult to interpret.
Recently, the study of patients from Poland allowed the identification of three patient-specific heterozygous variants in NANOS1 (51) (nanos C2HC-type zinc finger 1), a gene that is not required for spermatogenesis in the mouse (52) . One of the mutations, present in two unrelated infertile men, had been transmitted from the father, suggesting that this variant could not be the primary cause of the azoospermia in these two carriers. Further work is required to determine whether the other two alleles had an effect on male fertility.
Initial reports of genetic variants associated with male spermatogenic failure come most often from small single-center studies and larger multicenter studies are required to confirm or refute these preliminary observations (52, 53) . Such studies have been performed for three genes, MTHFR (54) (methylenetetrahydrofolate reductase), GSTM1 (55) (glutathione S-transferase mu 1) and FSHB (56) (follicle stimulating hormone beta subunit) revealing variants that are significantly associated with infertility, but have only a slight negative effect. This seems a logical outcome because a variant with a strong dominant negative impact on male fertility will be rapidly eliminated from the population.
An interesting case is NR5A1 (nuclear receptor subfamily 5, group A, member 1), which encodes the transcription regulator SF1, known to be important for the determination of the testis and gonadal development (57) . Three independent studies have found a variety of rare missense mutations in 0.6, 1.7 and 4% of men with azoospermia or SO, compared with 0% in controls (58) (59) (60) . These variants in most cases have been shown in vitro to reduce the transactivation potential of SF1.
From ExAC, it can be seen that more than half of them are present in multiple individuals with allele frequencies of up to 0.3%, in certain populations. This indicates that these NR5A1 variants are probably contributing risk factors for spermatogenic failure rather than primary dominant genetic causes.
In conclusion, the candidate gene approach has not been an efficient strategy for the identification of the genetic basis of male infertility and it has identified rare variants that each may have only a slight negative effect on fertility. In most cases, the impact of this type of heterozygous variant will only become clear once thousands of complete exome or genome sequence datasets for NOA and SO men are available in the public domain. For the moment, it is important to check allele frequencies in ExAC before building on these earlier studies or publishing similar findings.
Copy number variants and spermatogenic failure
Deletions or duplications can cause the copy number of large segments of the genome to vary. These genetic variations are known as copy number variants (CNV). Several groups have investigated the association of CNVs with NOA and SO and each study has identified patient-specific CNVs. A feature common to a number of studies is a CNV burden effect in infertile men compared with controls, based on both size of affected segment and frequency (40) . This is particularly pronounced on the sex chromosomes (40, 61, 62) . In one of the largest CNV studies so far (61), two regions were found to be deleted with a higher frequency in patients compared with controls. The first region, flanked by two quasi-identical blocks, is a 100 kb segment on Xp11.23 containing the sperm acrosome-associated protein gene SPACA5. This deletion was found in 2.8% of patients vs 0.7% of controls. The second deletion encompasses a segment of variable size around the testicular development gene DMRT1 (doublesex and mab-3 related transcription factor 1). It is found in 0.38% of patient vs 0% of controls. Furthermore, the combined frequency of deletions and duplications of the Y-chromosome tandem array DYZ19 were 4-5 times more frequent in patients compared with controls (6.1 vs 1.3%). In a second large pan-genome CNV study (63) , duplications of a minimal segment of 338 kb were described in three azoospermic men (n = 970) and 0 fertile controls (n = 1661). The duplicated segment located on chromosome 1 includes MAST2 (microtubule associated serine/threonine kinase 2) and a replication study found duplication of a marker in MAST2 in 0.7% of NOA men (n = 1457) and 0.06% of controls (n = 1590). The duplicated segment also includes two other genes IPP (intracisternal A particle-promoted polypeptide) and PIK3R3 (phosphoinositide-3-kinase regulatory subunit 3), both of which are expressed in testis, but these were not tested. Therefore it remains uncertain, which is the critical gene in the duplicated segment.
This suggests that CNV burden is a risk factor for male infertility, but also that there are no frequent recurrent large deletions or duplications apart from those that are already defined on the Y-chromosome. At the present time, it would appear that extensive CNV studies will define the cause of infertility and the gene involved in only a small percentage of cases.
Genome-wide association studies
Genome-wide association studies (GWAS) have also been used to define the genetic basis of male infertility. Comprehensive sets of the known genomic SNPs have been screened by microarray to identify variants that are associated with NOA. Although three studies have used this method to identify several variants significantly associated with NOA, there is no overlap between the genomic regions identified and risks conferred are low (64) (65) (66) . The fact that these GWAS have not detected any strong associations with male infertility is nevertheless a key result toward understanding the genetic landscape of human spermatogenic failure, as it indicates that there is no variant or mutated gene locus that is frequently a cause of NOA. These first GWAS results are consistent with a model of locus heterogeneity for the genetic causes of NOA. This is entirely consistent with two facts: the testis is the organ that expresses the highest number of tissue-specific transcripts (n ≥ 1000) (67) , and altered spermatogenesis has been observed in knockout mouse models for more than 388 genes (68).
The X-chromosome: TEX11 is mutated in 1% of azoospermic men One of the rare successes in identifying causal mutations has been with the X-chromosome meiotic gene TEX11 (Table 1 , TEX11 variants are designated on the basis of transcript ENST00000395889.). By targeted sequencing of TEX11, two groups have identified six different LOF mutations unique to azoospermic men (27, 29) . The frequency of these mutations is approximately 1% (6 LOF mutations in 535 men -3 in invariant splice site dinucleotides, 1 frameshift, and 2 in-frame deletions of 79 amino acids). No LOF mutations were found in controls or in the ExAC exome database (n = 60,706) providing important support for the causal nature of these mutations. In three of the men carrying a LOF mutation in TEX11, a testicular biopsy was available and showed maturation arrest (29) . This is consistent with data from the mouse, where the knockout of TEX11 is associated with meiotic arrest and azoospermia.
Two missense variants in TEX11 were also described as potentially causal in one study (29) , but they are found at too high a frequency in ExAC to have a strong dominant negative effect on male fertility: p.Met171Val -1 in 128 in the East Asian cohort and 1 in 282 in the African cohort; and p.Ala698Thr -1 in 121 in the African cohort.
The deletion of 79 amino acids, p.(Thr218_Lys 296del), a complex double-deletion and inversion that results in the loss of exons 10, 11 and 12, was found in two unrelated men (29) . Its complexity raises the possibility that this deletion has been transmitted from a founder individual, and that the deletion may thus be associated with a milder spermatogenic phenotype allowing its transmission. Compatible with this, the deletion does not introduce a frameshift, and one of the carriers has the milder phenotype of mixed testicular atrophy in which spermatogenesis progresses to post-meiotic stages in some tubules. An alternative explanation is that the deletion of the TEX11 exons occurred twice independently on X-chromosomes, where the inversion and deletion of the LINE1 repeat upstream of exon 10 already existed as a neutral polymorphism. This possibility should be investigated, because carriers of such a pre-mutated locus might have an increased risk of having offspring with fertility problems linked to compromised TEX11 function. Furthermore, it is not clear from Yatsenko et al. in which cohort the two p.(Thr218_Lys296del) deletions were found or whether matching control samples were screened to exclude the possibility of a polymorphism. Some minor doubts therefore remain that the p.(Thr218_Lys296del) deletion is causal of maturation arrest.
Nevertheless, TEX11 is the first and, so far, the only gene in which mutations causal of NOA have been validated by the discovery of distinct LOF mutations in unrelated men. It is intriguing that mutations on the X-chromosome, which should be negatively selected in male shall be found with such a high frequency in infertile men. Considering the presumed abundance of X-linked genes involved in spermatogenesis, numerous other rare X-linked variants are expected to be identified in the near future.
Autosomal recessive causes of azoospermia (Table 1) Studies of consanguineous families with multiple azoospermic sons have identified several strong candidates for genetic causes of autosomal recessive NOA. The first two candidate NOA mutations were described very recently in 2014 through the study of two consanguineous families (29, 30) . These were found in TAF4B, a testis-predominant transcription factor, and ZMYND15, a spermatid-specific histone deacetylase-dependent transcriptional repressor. The variants found in these genes are good candidates for mutations causal of NOA: the mutations (nonsense and 4 bp deletion) are predicted to prevent expression of the protein and the knockout of either gene in the mouse leads to isolated azoospermia.
In the past year, the study of consanguineous families has identified variants that may be the cause of autosomal recessive NOA in a further four genes, TEX15 (nonsense), MCM8 (splice), NPAS2 (missense) and SYCE1 (splice) (29, 33, 35, 37, 38) . Of these, the missense variant found in the NPAS2 gene requires further validation because NPAS2 expression predominates in the nervous system, not in the testis, and male mice lacking NPAS2 are fertile (39) . In contrast, TEX15, MCM8 and SYCE1 are predominately expressed in the testis and the rare homozygous LOF mutation identified for each gene is a strong indication that the gene is inactivated in infertile men. Furthermore, the knockout of Tex15, Mcm8 and Syce1 orthologues in mouse produces an azoospermia consequent to a meiotic block (28, 34, 36) . This is consistent with the phenotype observed in the infertile men carrying homozygous LOF variants in these three genes, further validating these mutations as causal of NOA. Supporting the case for a critical role during male and female meiosis for MCM8, an independent homozygous LOF mutation (frameshift) and a homozygous missense variant in MCM8 have been identified in women with primary amenorrhea, respectively, in two consanguineous families, but no homozygous brothers were studied (69) . No additional mutations have been identified in unrelated azoospermic men (n ≤ 100) for any of these genes, indicating that mutations in these genes are not frequent causes of NOA. Even though they may be extremely rare, it should not be forgotten that for strict validation of these variants as monogenic causes of severe spermatogenic failure, second independent cases with homozygous LOF variants are now required.
Obstructive defects
Although this review mainly focuses on genetic defects leading to altered sperm production, we cannot overlook the obstructive defects leading to obstructive azoospermia (OA) especially as a new gene has just been identified leading to OA.
Cystic fibrosis transmembrane conductance regulator
Analysis of the cystic fibrosis transmembrane regulator (CFTR) gene has until now been the main genetic test recommended for men diagnosed with CBAVD (70) . Together with karyotyping and screening for Y-microdeletions this trio has remained for decades the only genetic analyses proposed to azoospermic men (68) . CFTR codes for a chloride channel and the protein is found in the apical membrane of epithelial cells lining exocrine glands. Absence of this channel results in an imbalance of ion concentrations across the cell membrane. As a result, fluids secreted through these glands become more viscous and, in the end, ducts become congested and atrophy (71) . CFTR mutations have an autosomal recessive segregation pattern. Absence of a functional protein due to the presence on both alleles of severe mutations abrogating protein function leads to cystic fibrosis (CF), while the presence of a 'milder' mutation preserving some channel functionality combined with another mild or severe allele, gives rise to what has been described as CFTR-related disorder (CFTR-RD) (72) . The main CFTR-RDs are CBAVD, pancreatitis and bronchiectasis. Nearly, all CF patients are found to have CABVD while others with milder genotypes can have one or several of the described CFTR-RD syndromes. Similar to the other CFTR-RD syndromes, CBAVD is caused by mucus thickening and stagnation leading to infections and ultimately atresia. For this reason the term 'absence' is now preferred to the original 'agenesis' in the CBAVD acronym. This term is now commonly accepted but still appears imperfect as the disappearance of the vas deferens probably occurs in infancy or childhood and is thus probably rarely congenital. Over 2000 CFTR mutations have so far been described (http://www.genet.sickkids.on.ca/Home .html and http://cftr2.org/). A genetic diagnosis of CFTR mutation is important for CBAVD patients as it brings a good prognosis for the recovery of viable sperm from the epididymis or the testis. Testing for CFTR mutations in a CBAVD man and his partner is also critical to evaluate the risk of giving birth to a CF-affected child. If both parents are carriers, prenatal or pre-implantation diagnosis should be proposed to avoid the birth of CF-affected children. CFTR analysis should, however, be restricted to patients for whom agenesis of vas deferens has been confirmed by palpation and/or echography. This diagnosis is normally confirmed by low pH levels of the ejaculate due to the loss of seminal vesicles secretions.
Adhesion G protein-coupled receptor G2
CBAVD is found in more than 25% of men with OA (73) . At least one CFTR mutation is found in approximately 80% of men with CBAVD (74, 75) indicating that the origin of the CBAVD is unknown in at least 20% of cases. Patat et al. (76) analyzed a large cohort of CBAVD patients and selected those negative for CFTR mutations with a confirmed CBAVD diagnosis. They performed whole-exome sequencing (WES) on 12 patients and targeted sequencing on 14 additional individuals. They identified three distinct frameshift mutations in the ADGRG2 gene in four of the tested subjects (76) . ADGRG2 is an X-linked gene encoding one of 33 adhesion-class G protein-coupled receptors (adhesion-GPCRs) and is specifically expressed within the efferent ducts (77) . Adgrg2 mutant mice develop fluid accumulation in the testis ducts leading to an obstructive infertility phenotype, concordant with what has been described in ADGRG2 mutated men (78) . ADGRG2 testing should therefore be considered in CFTR negative CBAVD patients as this will improve diagnosis efficiency, reduce the risk of undetected mutant alleles of CFTR being present and allow appropriate genetic counseling.
Conclusion
Genetic causes of NOA remain largely unknown Despite many efforts directed toward the identification of the genetic basis of quantitative defects in human spermatogenesis, there is still little known about the mutations and the genes involved. The most productive area has been the study of consanguineous families, which has now identified the first five strong candidates for autosomal recessive causes of NOA. Potential dominant causes of NOA and SO have also been screened for, mainly using the candidate gene approach, but only large whole-genome CNV screens have had a few convincing successes. We should not conclude from these that genetic causes of spermatogenic failure are mainly recessive, because the consanguineous-family approach is heavily biased toward that outcome. Indeed the exciting finding that 1% of NOA can be explained by LOF mutations in the X-linked gene TEX11 would be consistent with a tractable model where dominant or X-linked mutations in tens of genes, rather than recessive mutations in thousands, could explain a large part of the genetic basis of NOA. Despite the successes, it is nevertheless clear that at present with less than 10 NOA/SO genes identified, we are far from establishing a gene-based classification of human male infertility associated with NOA or SO.
High-throughput sequencing and large cohort studies will exponentially increase the number of identified genes Recent technological advances have stimulated the search for genes involved in male infertility. These techniques, first homozygosity mapping using single nucleotide polymorphism (SNP) microarrays and more recently exome sequencing have allowed the identification of an increasing number of genetic defects associated with a variety of different types of male infertility. WES can now be performed for under 500 €/$. Studies of large cohorts of patients have therefore now become affordable and will enable the rapid identification of dozens or perhaps hundreds of new genetic causes of male infertility. Technological advances continue and whole-genome sequencing (WGS) will soon overtake WES. An important advantage of WGS over WES is that it does not necessitate the enrichment of the target sequence. This initial phase of exon capture, necessary for exome sequencing introduces important quantitative biases that complicate the detection of CNVs. With WGS, not only will it be possible to identify all genetic defects, irrespective of their position of the genome, but also it will be possible to detect all CNVs and to directly characterize their extent and localization. We are therefore convinced that the genetics of infertility will experience two successive golden eras, firstly the exomic era which has just begun but will be short lived (a few years) before being surpassed by a genomic era when the remaining genetic variants, that previous techniques were not able to detect, will be brought to light.
